What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Authors
Keywords
-
Journal
Current Diabetes Reports
Volume 20, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-11
DOI
10.1007/s11892-020-01347-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure
- (2020) Michael C. Honigberg et al. Circulation-Heart Failure
- Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
- (2020) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
- (2020) Kevin Damman et al. EUROPEAN JOURNAL OF HEART FAILURE
- Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction
- (2020) John R. Teerlink et al. JACC-Heart Failure
- Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
- (2020) João Pedro Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- (2020) Matthew Griffin et al. CIRCULATION
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
- (2020) Muthiah Vaduganathan et al. LANCET
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- (2020) Paul W. Armstrong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
- (2019) Orly Vardeny et al. JACC-Heart Failure
- Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis
- (2019) Muhammad Shahzeb Khan et al. European Journal of Preventive Cardiology
- Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
- (2019) Riobaldo Cintra et al. Revista da Associacao Medica Brasileira
- Longitudinal Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry
- (2019) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality
- (2019) Gianluigi Savarese et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
- (2019) Felipe A. Martinez et al. CIRCULATION
- SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
- (2019) Carolyn S. P. Lam et al. Journal of the American Heart Association
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure
- (2018) Abhinav Sharma et al. Circulation-Heart Failure
- Medical Therapy for Heart Failure With Reduced Ejection Fraction
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
- (2018) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists
- (2016) David Z.I. Cherney et al. CIRCULATION
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
- (2016) Matthew R. Weir POSTGRADUATE MEDICINE
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
- (2015) Alessandra Dei Cas et al. JACC-Heart Failure
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes and Insulin Resistance in Older People
- (2011) Adie Viljoen et al. MEDICAL CLINICS OF NORTH AMERICA
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
- (2010) M. Komajda et al. EUROPEAN HEART JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now